Gyre Therapeutics, Inc. (GYRE) stock
GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3014% below fair value
$4.34−0.22 (-4.82%)
Close on Nov 18, 2026Market cap $483.95MP/E –Yield –
Gyre Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Gyre Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -14.4%. For fiscal 2025 it was 9.9%, against 15.3% the year before. The highest annual figure on record is 15.3% in fiscal 2010.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9.9% | −5.4 |
| FY2024 | Dec 31, 2024 | 15.3% | +74.5 |
| FY2023 | Dec 31, 2023 | -59.3% | −68.3 |
| FY2022 | Dec 31, 2022 | 9.0% | +1206.8 |
| FY2021 | Dec 31, 2021 | -1197.8% | −923.9 |
| FY2020 | Dec 31, 2020 | -273.9% | +563426.1 |
| FY2018 | Dec 31, 2018 | -563700.0% | −561556.4 |
| FY2017 | Dec 31, 2017 | -2143.6% | +586.9 |
| FY2014 | Dec 31, 2014 | -2730.5% | −2451.7 |
| FY2013 | Dec 31, 2013 | -278.9% | −264.8 |
| FY2012 | Dec 31, 2012 | -14.1% | −4.1 |
| FY2011 | Dec 31, 2011 | -10.0% | −25.3 |
| FY2010 | Dec 31, 2010 | 15.3% | +176.2 |
| FY2009 | Dec 31, 2009 | -160.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -4.6% | −9.2 |
| Q2 FY2026 | Jun 30, 2026 | -49.3% | −41.8 |
| Q1 FY2026 | Mar 31, 2026 | -41.5% | −51.8 |
| Q4 FY2025 | Dec 31, 2025 | 41.1% | +38.7 |
| Q3 FY2025 | Sep 30, 2025 | 4.6% | −12.0 |
| Q2 FY2025 | Jun 30, 2025 | -7.5% | −20.2 |
| Q1 FY2025 | Mar 31, 2025 | 10.3% | −19.4 |
| Q4 FY2024 | Dec 31, 2024 | 2.4% | +339.9 |
| Q3 FY2024 | Sep 30, 2024 | 16.6% | −23.2 |
| Q2 FY2024 | Jun 30, 2024 | 12.7% | −4.3 |
| Q1 FY2024 | Mar 31, 2024 | 29.7% | +3.0 |
| Q4 FY2023 | Dec 31, 2023 | -337.5% | +1514.0 |
| Q3 FY2023 | Sep 30, 2023 | 39.8% | +872.3 |
| Q2 FY2023 | Jun 30, 2023 | 17.0% | +1114.3 |
| Q1 FY2023 | Mar 31, 2023 | 26.7% | +1785.9 |
| Q1 FY2022 | Mar 31, 2022 | -1851.5% | −322.0 |
| Q4 FY2021 | Dec 31, 2021 | -832.5% | +95.2 |
| Q3 FY2021 | Sep 30, 2021 | -1097.4% | +705.5 |
| Q2 FY2021 | Jun 30, 2021 | -1759.2% | −712.1 |
| Q1 FY2021 | Mar 31, 2021 | -1529.5% | −1498.5 |
| Q4 FY2020 | Dec 31, 2020 | -927.7% | +110389.0 |
| Q3 FY2020 | Sep 30, 2020 | -1802.9% | +30.1 |
| Q2 FY2020 | Jun 30, 2020 | -1047.1% | +801.3 |
| Q1 FY2020 | Mar 31, 2020 | -31.0% | +5324.0 |
| Q1 FY2018 | Mar 31, 2018 | -111316.7% | – |
| Q4 FY2017 | Dec 31, 2017 | -1833.0% | – |
| Q3 FY2017 | Sep 30, 2017 | -1848.4% | – |
| Q2 FY2017 | Jun 30, 2017 | -5355.0% | – |
See a number that looks wrong?